While Novartis News Today

NORTHAMPTON, MA / ACCESSWIRE / February 7, 2023 / Novartis is a focused medicines company with a purpose to reimagine medicine to improve and extend people's lives. On February 1, we published our Novartis

Zolgensma may stop five-year-old Yusuf Polat’s spinal muscular atrophy from progressing, but it costs $2.1m.

When Novartis reported first-half Zolgensma sales a few months ago, the company said its spinal muscular atrophy gene therapy was growing thanks to "expanding access" in Europe. This week at the Fierce Biotech Cell & Gene Therapy event, an exec outlined what's driving the uptake.